

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

NCI-H2030

RRID:CVCL_1517

Type: Cell Line

Proper Citation

RRID:CVCL_1517

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1517

Proper Citation: RRID:CVCL_1517

Description: Cell line NCI-H2030 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:8806092](#), [PMID:11030152](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2030

Synonyms: H2030, H-2030, NCIH2030

Cross References: BTO:BTO_0006438, CLO:CLO_0008041, EFO:EFO_0002274, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5914, BioGRID_ORCS_Cell_line:534, BioSample:SAMN03471413, BioSample:SAMN10988239, cancercellines:CVCL_1517, Cell_Model_Passport:SIDM00715, ChEMBL-

Cells:CHEMBL3308769, ChEMBL-Targets:CHEMBL1075530, Cosmic:722045, Cosmic:903611, Cosmic:1146897, Cosmic:1609520, Cosmic:1995553, Cosmic-CLP:722045, DepMap:ACH-000521, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:722045, GEO:GSM206483, GEO:GSM274747, GEO:GSM274748, GEO:GSM434332, GEO:GSM784272, GEO:GSM794344, GEO:GSM817097, GEO:GSM887397, GEO:GSM888475, GEO:GSM1374717, GEO:GSM1670208, IARC_TP53:21552, IGRhCellID:NCIH2030, LiGeA:CCLE_404, LINCS_LDP:LCL-1648, PharmacDB:NCIH2030_1058_2019, PRIDE:PXD030304, Progenetix:CVCL_1517, PubChem_Cell_line:CVCL_1517, Wikidata:Q54907906

ID: CVCL_1517

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260829T234731+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2030.

No alerts have been found for NCI-H2030.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. *Molecular cell*, 86(8), 1546.

Bai Y, et al. (2026) Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. *Cancer discovery*, 16(1), 135.

Zhu G, et al. (2026) Accumulated sotorasib-bound KRASG12C reactivates the MAPK pathway and drives sotorasib resistance via the DHX9-RAC1-PAK1 axis. *Cell reports*, 45(5), 117338.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. *Oncogene*, 45(31), 3244.

He D, et al. (2026) Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases. *Journal of the National Cancer Center*, 6(3), 286.

Hu Z, et al. (2026) Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. *Immunity*, 59(7), 1928.

Jameson NM, et al. (2025) The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models. *Cancer research communications*, 5(2), 240.

Daley BR, et al. (2025) SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma. *Cancer research*, 85(1), 118.

Zhu T, et al. (2025) Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. *Molecular cell*.

Liu C, et al. (2025) Chronic Stress Stimulates Protumor Macrophage Polarization to Propel Lung Cancer Progression. *Cancer research*, 85(13), 2429.

Negrao MV, et al. (2025) Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(6), 1069.

Pan K, et al. (2025) ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non-small cell lung cancer. *The Journal of biological chemistry*, 302(2), 111110.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Zhang Q, et al. (2025) PLK1-mediated PDHA1 phosphorylation drives mitochondrial dysfunction, mitophagy, and cancer progression in Cr(VI)-associated lung cancer. *The Journal of biological chemistry*, 301(7), 110406.

Maso L, et al. (2025) Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy. *Nature communications*, 16(1), 11264.

Pulawska-Moon K, et al. (2024) Novel ectopic expression of zona pellucida 3 glycoprotein in lung cancer promotes tumor growth. *International journal of cancer*.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Thatikonda V, et al. (2024) Genetic dependencies associated with transcription factor activities in human cancer cell lines. *Cell reports*, 43(5), 114175.

Ye F, et al. (2023) TGF β Antagonizes IFN γ -Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma. *Cancer research*, 83(13), 2262.

Cheung AH, et al. (2023) MLK4 promotes glucose metabolism in lung adenocarcinoma through CREB-mediated activation of phosphoenolpyruvate carboxykinase and is

regulated by KLF5. *Oncogenesis*, 12(1), 35.